Search hospitals
>
Nevada
>
Las Vegas
Comprehensive Cancer Centers of Nevada
Claim this profile
Las Vegas, Nevada 89148
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Prostate Cancer
Conducts research for Pancreatic Cancer
464 reported clinical trials
16 medical researchers
Summary
Comprehensive Cancer Centers of Nevada is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Prostate Cancer, Pancreatic Cancer and other specialties. Comprehensive Cancer Centers of Nevada is involved with conducting 464 clinical trials across 475 conditions. There are 16 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Fadi Braiteh, MD, and Nicholas Vogelzang, MD.
Area of expertise
Lung Cancer
Comprehensive Cancer Centers of Nevada has run 90 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
Comprehensive Cancer Centers of Nevada has run 89 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
John A. Ellerton
OptumCare Cancer Care at Fort Apache
7 years of reported clinical research
Alan K. Ikeda
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
8 years of reported clinical research
Fadi Braiteh, MD
Comprehensive Cancer Centers of Nevada
7 years of reported clinical research
Nicholas Vogelzang, MD
Comprehensive Cancer Centers of Nevada
6 years of reported clinical research
Clinical Trials running at Comprehensive Cancer Centers of Nevada
Breast Cancer
Cancer
Prostate Cancer
Lung Cancer
Bladder Cancer
Ovarian Cancer
Esophageal cancer
Colorectal Cancer
Esophageal Cancer
Breast cancer
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting
2 awards
Phase 3
6 criteria
PF-07248144 + Fulvestrant
for Breast Cancer
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another. This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle. The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.
Recruiting
2 awards
Phase 3
4 criteria
Sacituzumab Tirumotecan + Pembrolizumab
for Breast Cancer
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Recruiting
2 awards
Phase 3
3 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Comprehensive Cancer Centers of Nevada?
Comprehensive Cancer Centers of Nevada is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Prostate Cancer, Pancreatic Cancer and other specialties. Comprehensive Cancer Centers of Nevada is involved with conducting 464 clinical trials across 475 conditions. There are 16 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Fadi Braiteh, MD, and Nicholas Vogelzang, MD.
Where is Comprehensive Cancer Centers of Nevada located?
The Comprehensive Cancer Centers of Nevada is located at 7445 Peak Dr., Las Vegas, NV 89128. For directions, from downtown Las Vegas, take I-15 N to US-95 N towards Henderson, exit 81A for Summerlin Pkwy W, continue on Lake Mead Blvd, then turn right onto Peak Dr. The hospital will be on your left.
Who should I call to ask about financial aid or insurance network?
For general health insurance inquiries in Nevada, contact the Office of the Consumer Health Advocate at 1-888-333-1597. For employer-provided insurance questions, reach out to the Nevada Division of Insurance at (888) 872-3234. Comprehensive Cancer Centers of Nevada offers financial counseling to assist with treatment costs and insurance matters; visit their Contact Us page for more information.
What insurance does Comprehensive Cancer Centers of Nevada accept?
The Comprehensive Cancer Centers of Nevada accept a wide range of insurance plans, including commercial insurance, Medicare, Medicare Part C, Medicaid in some cases, and certain U.S. Department of Veterans Affairs and TRICARE plans. For detailed information on coverage, it is recommended to contact an Oncology Information Specialist at the center.
What awards or recognition has Comprehensive Cancer Centers of Nevada received?
Comprehensive Cancer Centers of Nevada (CCCN) is recognized for its excellence in clinical care and research, having been designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI). Its physicians were named Best Doctors by Healthcare Quarterly and Desert Companion in 2021. CCCN actively participates in over 170 clinical trials annually, contributing to the development of more than 100 FDA-approved cancer therapies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.